Transcode Therapeutics, Inc. — Form D
Transcode Therapeutics, Inc. of BOSTON, MA, a company, filed a Form D exempt-offering notice with the SEC on 2024-12-12. The offering totals $8.0M, of which $8.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2024-12-12
- Form: D
- Accession: 0001104659-24-128019
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $8.0M
- Amount sold: $8.0M
- Investors: 6
- Date of first sale: 2024-12-02
- Security types: equity
- Revenue range: No Revenues
- SEC file number: 021-531946
Issuer
- Name: Transcode Therapeutics, Inc.
- CIK: 0001829635
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Address: 6 LIBERTY SQUARE, #2382, BOSTON, MA, 02109
- Phone: 857-837-3099
Officers, directors & promoters (5)
| Name | Role | Location |
|---|
| Philippe A Calais | Director | Boston, MA |
| Thomas A Fitzgerald | Director | Watertown, MA |
| Erik A Manting | Director | Boston, MA |
| Magda A Marquet | Director | Boston, MA |
| Thomas A Fitzgerald | Executive Officer | Watertown, MA |
More